Rena Conti

Jan 18, 2025 | onlinelibrary.wiley.com | Rena Conti |Patrick C. DeMartino |Jonathan Gruber |Andrew Lo

Cell and gene therapies (CGTs) are highly innovative medicines. There are over two dozen CGTs approved for sale globally, and over the last five years, many clinical trials have progressed toward later stages of development targeting an array of rare genetic disorders and cancers.1, 2 CGTs come with a host of challenges for health care systems, of which perhaps the foremost is affordability.3-5 CGTs are extremely expensive,6 generally in the range of more than $300,000.

Mar 5, 2024 | aei.org | Amitabh Chandra |Matthew Vogel |Rena Conti

The Inflation Reduction Act (IRA) of 2022 is the most significant reform to US prescription drug pricing in two decades and the first expected to result in a net reduction in Medicare drug costs. Although beneficial for today’s payers and patients, the magnitude of the law’s effect on future innovation is disputed. The Congressional Budget Office (CBO) estimated that the IRA will result in a decrease of one new drug in the first decade and an additional 12 drugs over the following two decades.

Mar 5, 2024 | healthaffairs.org | Matthew Vogel |Rena Conti |Amitabh Chandra

The Inflation Reduction Act (IRA) of 2022 is the most significant reform to US prescription drug pricing in two decades and the first expected to result in a net reduction in Medicare drug costs. Although beneficial for today’s payers and patients, the magnitude of the law’s effect on future innovation is disputed. The Congressional Budget Office (CBO) estimated that the IRA will result in a decrease of one new drug in the first decade and an additional 12 drugs over the following two decades.

Jan 11, 2024 | brookings.edu | Marta Wosinska |Rena Conti |Elisabeth B. Reynolds

On March 2, 2023, the authors convened a group of experts from academia, industry, government, and nonprofits to explore technology options for increasing the resilience in the supply of generic prescription drugs. The workshop was convened at the Massachusetts Institute of Technology with the help of the National Network for Critical Technology Assessment and financial support from the Alfred P. Sloan Foundation. This report, authored by the organizers, summarizes the discussion.

Nov 1, 2023 | brookings.edu | Marta Wosinska |Rena Conti

In October 2023, Marta Wosińska and Rena Conti concluded a one-year pilot demonstration of how analytics can inform national technology strategy in biopharmaceuticals. Their demonstration was part of a large, cross-industry pilot titled the National Network for Critical Technology Assessment.